Signaling pathway between
human leukocyte antigen (
HLA)-G and immune inhibitory receptors
immunoglobulin-like transcript (ILT)-2/4 has been acknowledged as one of immune checkpoints, and as a potential target for
cancer immunotherapy. Like other immune checkpoints, inter- and even intratumor heterogeneity of
HLA-G could render a rather complexity for
HLA-G-target
immunotherapy. However, little information for intratumor heterogeneity of
HLA-G is available. In this study,
HLA-G expression in a serial section of
colorectal cancer (CRC) lesions from three CRC patients (each sample with serial section of 50 slides, 10 randomized slides for each antibody), three different locations within a same sample (five CRC), and three case-matched blocks that each includes 36
esophageal cancer samples, were evaluated with immunohistochemistry using anti-
HLA-G antibodies (mAbs 4H84, MEM-G/1 and MEM-G/2 probing for all denatured
HLA-G isoforms, 5A6G7, and 2A12 probing for denatured HLA-G5 and HLA-G6
isoforms). Our results revealed that, in addition to the frequently observed inter-
tumor heterogeneity, intratumor heterogeneous expression of
HLA-G is common in different areas within a
tumor in CRC and
esophageal cancer samples included in this study. Moreover, percentage of
HLA-G expression probed with different anti-
HLA-G antibodies also varies dramatically within a
tumor. Given
HLA-G has been considered as an important immune checkpoint, intratumor heterogeneity of
HLA-G expression, and different specificity of anti-
HLA-G antibodies being used among studies, interpretation and clinical significance of
HLA-G expression in
cancers should be with caution.